Latest News

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Sett...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperi...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone)

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovat...

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation a

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Confer...

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the T...

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatm

Teva Initiates Voluntary Nationwide Recall of one (1) Lot of Metoclopramide Tablets USP, 10mg

Teva Initiates Voluntary Nationwide Recall of one (1) Lot of Metoclopramide Tablets USP, 10mg

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool ...

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tende

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds...

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to R

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Gr...

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Li...

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~4...

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2